Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-11-11

Clinical Trial Update: A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients [Phase 1]

View source ↗

Summary

A completed Phase I trial evaluating the combination of bevacizumab and sunitinib in patients with metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • Sunitinib (sunitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Renal Cell Carcinoma, Kidney Cancer | Phase 1 | Status: COMPLETED